H. Einsele et al., Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection, BONE MAR TR, 25(7), 2000, pp. 757-763
Citations number
31
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
PCR-based preemptive therapy with ganciclovir has been shown to reduce the
incidence of CMV disease after BMT, Failures of this treatment strategy are
CMV disease and secondary non-viral infections. Eighty-six consecutive pat
ients at high risk for CMV disease who received PCR-based preemptive therap
y with ganciclovir were assessed for treatment failures and possible risk f
actors. Ganciclovir was initiated in 57 of 86 patients (66%), Only 28 of 86
(32%) patients received 4 or more weeks of ganciclovir, Recurrence of CMV
infection after successful treatment was more frequent among recipients of
a BMT from an unrelated compared to a sibling donor (P = 0.004). Three (3.5
%) patients developed non-fatal early onset CMV disease and seven of 68 (10
.3%) late onset CMV disease (>100 days post transplant). Risk factors for l
ate onset CMV disease were cGVHD (P = 0.0017) and duration of prior antivir
al therapy >4 weeks (P = 0.0073). The incidence of secondary non-viral infe
ctions was 28% with the duration of antiviral treatment being a significant
risk factor for secondary bacterial (P = 0.0045) and invasive fungal infec
tions (P = 0.006). Thus, PCR-based preemptive treatment with ganciclovir re
duces early onset CMV disease, but the duration of antiviral therapy prior
to day +100 is a significant risk factor for late onset CMV disease as well
as secondary non-viral infections.